Epic Sciences Workshop | Digital Event

epic sciences

Beyond Enumeration: The Next Generation of Circulating Tumor Cell Technology

This Workshop ran on Wednesday November 17, 2021 | 11:00am ET | 8:00am PT

Beyond Enumeration: The Next Generation of Circulating Tumor Cell Technology

The Epic Sciences Workshop has been created exclusively to provide an in-depth understanding of how combining different aspects of liquid biopsies (LBx) can improve cancer characterization.

Circulating Tumor Cells (CTCs) have been traditionally counted and analyzed for prognostic purposes, however, advances in protein and genomic techniques have increased the information these cells can provide. Join this workshop to learn how CTCs and associated technologies can provide tumor characterization exceeding that provided by tissue alone.

This is the perfect opportunity for Directors, Heads & Leaders from Translational Medicine, Clinical Biomarker & Diagnostics departments from biopharma to learn about CTC capabilities and how these can be applied to clinical trials, patient care and to maximize your clinical development strategy.

EXPERT SPEAKERS:

Jason Christiansen

Chief Technology Officer

Epic Sciences

Jiyun Byun

Director, Computer Vision Technologies

Epic Sciences

John Luecke

Director of Business Development

Epic Sciences

Peter Kuhn

Dean’s Professor of Biological Sciences

University of Southern California

Richard Wenstrup

Chief Medical Officer

Epic Sciences

ABOUT EPIC SCIENCES

epic sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and noninvasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer.

www.epicsciences.com